Platelet adhesion to fibrin at high shear rates depends on both the glycoprotein (GP) 1lb:llla complex and a secondary interaction between GPlb and von Willebrand factor (vWF). This alternative link between platelets and vWF in promoting platelet adhesion to fibrin has been examined in flowing whole blood with a rectangular perfusion chamber. Optimal adhesion required both platelets and vWF, as shown by the following observations. No binding of vWF could be detected when plasma was perfused over a fibrin surface or when coated fibrinogen was incubated with control plasma in an enzyme-linked immunosorbent assay. However, when platelets were present during perfusion, interactions between vWF and fibrin could be visualized with immunoelectron microscopy. Exposure of fibrin surfaces to normal
not exposed to a stimulus, adherent to surface-bound vWF primarily via GPIb and subsequently via GP1Ib:IIIa.' Studies of platelet adhesion to subendothelium or collagen under flow conditions also showed that vWF interacts with GPIb as well as GPIIb:IIIa. '9-22 We have studied here in detail the role of vWF in the interaction of platelets with fibrin under flow conditions. We show that only GPIb and not GP1Ib:IIIa interacts with vWF and that the binding of vWF to platelets is a prerequisite for binding of functional vWF to fibrin.
MATERIALS AND METHODS

Materials. Human
fibrinogen was purchased from KabiVitrum (Stockholm, Sweden) and Kordia (Enzyme Research Laboratories, South Bend, IN). Each fibrinogen preparation was dissolved in distilled deionized water at room temperature, dialyzed for 6 hours against distilled deionized water at room temperature, clarified by centrifugation, and stored at -20°C. The concentration was determined by absorbance measurements using an extinction coefficient at 280 nm of 1.6 mL/mg/cm, as previously de~cribed.~ No difference in clottability or vWF contamination was found between the different fibrinogen preparations. Fibrinogen was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the typical three-band pattern was present. The fibrinogen clottability was 95% to 9 9 6 , a s determined according to Clauss." The vWF antigen concentration was less than 0.6 ng/mg fibrinogen, and this vWF concentration in itself did not support adhesion under the conditions studied, Thrombin was purchased from Sigma (St Louis, MO). Microtiter plates were purchased from Costar (Cambridge, MA). All other chemicals were of analytical grade.
Characteristics qf adhesion inhibitors. Monoclonal anti-vWF antibody (MoAb) CLB-RAg35 ( a n t i -~W~" ' *~) , which blocks vWF binding to GPIb at 1 ~g / r n L ,~~ and control antibody CLB-RAgSO (anti-vWF, which does not influence a known function of vWF)*' were provided by Dr J.A. van Mourik (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands). MoAb 152B6 (anti-~WF'~""~~", blocks vWF binding to GPIIb-IIIa at 50 wg/mL IgG) was provided by Dr Z.M. Ruggeri (Scripps Research Institute, La Jolla, CA).'" IgG2.2.9 is an irrelevant antibody to platelets and was used as a control for 152B6.
Anti-GPIb antibody AK2 specifically blocks vWF interaction with GPIb. AK2 completely inhibited ristocetin-induced platelet agglutination in a 1:6,OOO dilution. In perfusion experiments, a 1 : 1 , m dilution was used. AK2 was a generous gift of Dr M. Bemdt vWF, AAl-VWF, and Dl746G-vWF. vWF was prepared from human cryoprecipitates using polyethyleneglycol precipitation and gel filtration on Biogel A-15m (BioRad, Richmond, CA)?6 Agarose gel electrophoresis showed the presence of predominantly the high molecular weight forms of vWF.
An EcoRI fragment containing full-length vWF cDNA was obtained from pSP8800-vWFz7 and clonedz8 into the mammalian expression vector pNUTz9 yielding p m -v W F . An Eag I-EcoRV fragment that lacks the coding sequence for amino acid 478-716 obtained from pSV2-AAI-vWF" was cloned into pNUT-vWF yielding p m -A A 1 -v W F . D1746G-vWF was made by changing the nucleotide positions 7527 and 7528 from AC to GA, resulting in the substitution of amino acid Asp(D)-1746 in Gly(G)-1746. After performing site-directed mutagenesis, the cDNA insert was sequenced3' and the mutations were found to be present. An Eag I-EcoRV fragment containing the mutation was cloned into the pNUT expression vector yielding pNUT-Dl746G-vWF. BHK-21 cells were transfected with the pNUT vectors using the calcium phosphate method, as described previou~ly.~~ After transfection, media of the cell cultures were harvested and the expression of rvWF was confirmed using an enzymelinked immunosorbant assay (ELISA).
Perfusion procedures. Whole blood obtained by venepuncture from healthy, volunteer donors was anticoagulated with 1/10 v01 trisodium citrate (120 mmol/L) and used directly for perfusion experiments. One hundred microliters of fibrinogen (200 pg/mL) or fibrinogen and thrombin (0.4 National Institutes of Health units [NIH U]/mL) in 50 mmol/L ammonium acetate buffer, pH 7.4, was sprayed onto glass coverslips to obtain a coating density of 6 pg/ cmZ. The coverslips were dried overnight at room temperature and washed extensively before use in perfusion experiments." It was previously shown that similar perfusion profiles resulted from fibrincoated coverslips that were kept in phosphate-buffered saline (PBS) until their use in perfusion experiment^.^
In some experiments, blood of a patient with Glanzmann's thrombasthenia, Bernard-Soulier syndrome, Macrothrombocytopenia, May-Hegglin, or severe von Willebrand's disease (vWD) was used. Double perfusions were performed as follows. The first perfusion run was with vWF-depleted plasma (0.5 pg/mL antigen concentration) or with normal plasma and red blood cells over a fibrin-coated surface. The second perfusion run involved whole severe vWD blood or control blood.
The role of platelet-vWF in supporting platelet adhesion to fibrin at high shear rate was tested with reconstituted blood. Therefore, washed platelets (200 X IO9 platelet&) and red blood cells (40% vol/vol) were reconstituted in a 4% human albumin solution (HAS; Krebs-Ringer buffer, 5 mmol/L aD-glucose, pH 7.4)33 without fibrinogen and vWF or with fibrinogen (2.5 g/L) and vWF (10 pg/ mL) in a total volume of 15 mL.
Perfusates were prewarmed at 37°C for 10 minutes and then recirculated through the perfusion chamber4 for 5 minutes at wall shear rates of 340/s or 1,600/s. Each perfusion involved a separate 15-mL aliquot of whole blood that was recirculated through the perfusion chamber at 34 &min (340/s) or 57 &min (1,600/s). Platelet activation and platelet loss during perfusion was determined with an ELISA for P-thromboglobulin (Diagnostica Stago, Amiers-surSeine, France) and single particle count, respectively. Platelet activation during perfusion was negligible and minimal platelet loss occurs during 5-minute recirculating perfusion experiments. After perfusions, the coverslips were removed, rinsed with HEPES-buffered saline (HBS; 10 m o V L HEPES, 150 mmol/L NaCl, pH 7.4). fixed in 0.5% glutaraldehyde, dehydrated in methanol, and stained with May-GrUnwald Giem~a.3~ The extent of surface coverage by adherent platelets was evaluated by light microscopy at 1,000~ magnification, aided by an image analyzer ( A M s 40-10, Saffron Walden, UK). Thirty randomly selected areas of each coverslip were evaluated and the results from duplicate coverslips were averaged. Statistical significance of the difference between means was determined with the paired t-test.
lmmunocytochemistry procedures for scanning electron microscopy (SEM) and intermediate voltage electron microscopy (ZVEM). In selected perfusions, coverslips containing gold grids covered with formvar and coated with fibrin were placed in the perfusion chamber. The fibrin-coated formvar grid coverslips were washed with HBS after perfusion to remove nonadherent cells and then fixed with 1% glutaraldehyde in HBS. After fixation, the samples were washed in Gey's buffer (Gey's balanced salt solution: 137 mmol/L NaCI, 2 mmol/L NazC03) with 0.1% glycine, pH 7.3, and incubated for 20 minutes in blocking buffer containing 2% gelatin and 5% bovine serum albumin in Gey's buffer. The coverslips were incubated overnight at 4°C with a primary polyclonal goat anti-vWF antibody (1 :200, IgG fraction; American Diagnostica, Greenwich, CT). After additional washes with Gey's buffer, a secondary rabbit antigoat antibody conjugated to 15-nm gold beads (Janssen Auroprobes RAG 15; Janssen Life Sciences, Olen, Belgium) was added. In some experiments, rabbit antimouse antibody conjugated to 5-nm gold beads (Janssen Auroprobes RAM 5 ) was included as a control for nonspecific secondary antibody binding. After 2 hours of incubation, the coverslips were washed, fixed with 1% glutaraldehyde in Gey's buffer, and washed with Gey's buffer followed by 0.1 molL sodium cacodylate buffer. The coverslips were postfixed with 0.5% OS04 in 0.1 mom sodium cacodylate buffer, washed with 0.1 moln sodium cacodylate buffer, stained with 0.5% aqueous uranyl acetate, dehydrated through a graded ethanol series, and critical point dried. The samples for SEM were coated with a thin layer of gold palladium, whereas IVEM samples were coated with a thin carbon film. For IVEM, the grids were examined in a Philips CM-30 (Philips, Eindhoven, The Netherlands) operated at an accelerating voltage of 300 keV. Both low magnification overviews and a higher magnification stereo tilt series, from +6 to -6 degrees, were recorded for each specimen.
Patients with Glanvnann's thrombasthenia, Bernard-Soulier syndrome, and severe vWD. Perfusions were performed with citrated blood from a patient with Glanzmann's thrombasthenia. GPIIb-IIIa on platelets of this patient was absent when measured by flow cytometry, and ADP stimulation did not produce platelet aggregation. Perfusions were also performed with citrated blood from a patient with Bernard-Soulier syndrome. The platelets were deficient in GPIb when measured by flow cytometry. The platelet count of this patient was approximately 30 X IO9 platelets/L and the platelet volume was 19 a, compared with 100 to 400 X IO9 plateletsn and 6 to 8 fL for normal donor platelets. No agglutination of the platelets in the presence of ristocetin and normal plasma was observed with these patient platelets. In addition to whole blood controls, control perfusions for the patient with Bernard-Soulier syndrome were performed with the citrated blood of a patient with macrothrombocytopenia (platelet count, 240 X IO9 platelets& platelet volume, 14 a) or with 3 patients with May-Hegglin's disease (platelet count, 20 to 70 X 10' platelets&; platelet volume, 14 a). These large platelets have normal GPIb and the blood is therefore used as a control for the patient with Bernard-Soulier syndrome. Perfusions were also performed with citrated blood obtained from a patient with severe vWD. Plasma and platelets of this patient contained less than 1% of the vWF of control values.
Binding of vWF to jbrinogen. An ELISA system was used to measure vWF binding to fibrinogen. Fibrinogen (200 pL) at a concentration of 0.1 mg/mL in PBS (0.1 m o m sodium phosphate buffer, 150 mmom NaCI, pH 7.4) was incubated in the wells of microtiter plates for 2 hours at 37°C. Each well was blocked with 200 pL of Michaelis buffer containing 3% bovine serum albumin and 0.1% Tween. Purified plasma vWF (100 pL) at a concentration of 10 pg/ mL or normal pool plasma (100 pL) was incubated with the fibrinogen-coated plates for 1 hour at 37°C. Detection involved a rabbit 
Whole blood from a patient with Glanzmann's thrombasthenia and a normal donor was perfused for 5 minutes at a wall shear rate of 340/s. Whole blood from a patient with Bernard-Soulier syndrome, individuals with macrothrombocytopenia, individuals with May-Hegglin's disease, a severe vWD patient, and normal donors was perfused for 5 minutes at a wall shear rate of 1,600/s for (n) observations. The results are expressed as the mean I SD percentage of surface covered by adherent platelets. 
RESULTS
Platelet,fihrin interaction studies with blood of GPllhrllla-.
GP& and vWF-deficient patients.
When a fibrin-coated glass surface was perfused with whole blood for 5 minutes, more than 40% of the surface was covered with platelets ( Table 1) . When the surface was perfused with the blood of a patient with Glanzmann's thrombasthenia, platelet coverage decreased to less than 2%. This finding confirmed our earlier observations that GPI1b:IIla is essential for platelet interaction with fibrin.
Decreased platelet adhesion to fibrin was found when platelets were used from a patient with Bernard-Soulier syndrome. The decrease in adhesion was more pronounced at a shear rate of 1,6OO/s ( Table 1) . Studies with the blood of a patient with Bernard-Soulier syndrome were hampered by the fact that not only the GP1b:IX complex was absent on these platelets but also the platelet number was low and the platelet volume was large. Therefore, results of studies with platelets of the patient with Bernard-Soulier syndrome were compared with the results of studies of platelets from individuals suffering from May-Hegglin's disease or macrothrombocytopenia. Those platelets were also large and their number was low, but GP1b:IX was normally expressed. The results with the Bernard-Soulier syndrome platelets were in agreement with the results found in the blood of a patient with severe vWD, in that a comparable decrease in adhesion to fibrin was found at high shear rate (Table I) . Thus, patients either lacking platelet GPIb or vWF are both defective in platelet adhesion to fibrin. This finding further supports the hypothesis of an alternative link between platelets and vWF via GPlb in promoting platelet adhesion to fibrin.
Morphologv of platelet adhesion to jhrin. Fibrin-coated coverslips were perfused for 5 minutes with whole blood at a shear rate 1.600/s. After staining, the coverslips were analyzed by light microscopy (Fig IA) . Platelets adhering to fibrin were often found in a band pattern consisting of strips of spread and dendritic platelets alternating with clear areas. Few raised aggregates were seen. When whole blood of a patient with severe vWD was perfused over fibrin under the same conditions, spread and dendritic platelets were randomly distributed but not in bands aligned the flow direction For Fig IB) . When normal whole blood was used at low shear rate, the surface is covered with platelets without a visible band pattern (Fig IC) . Comparable results were observed for fibrinogen as an adhesive surface (data not shown) and when heparin instead of citrate was used as anticoagulant (data not shown).
Light microscopy of platelets adherent to fibrin-coated formvar grids obtained from perfusion experiments with control blood showed a band pattern of spread and dendritic platelets identical to platelets adhered to fibrin coated on glass coverslips (Fig 2A) . Experiments with blood from a patient with macrothrombocytopenia (Fig 2B) or blood from the patient with Bernard-Soulier syndrome (Fig 2C) showed platelets with morphologies ranging from dendritic to fully spread. In contrast, only dendritic platelets were seen, but no spreading was observed, when the blood of a patient with Glanzmann's thrombasthenia was perfused (data not shown).
IVEM and immunogold labeling with an antibody against vWF resulted in clusters of gold around the granulomere of the spread control platelets. In addition, large filamentous structures showed intense staining for vWF (Fig 3A) . These filamentous structures were often seen extended between adherent platelets, but they also connected the platelet surface and the fibrin matrix. Quantitative analysis of fibrincoated grids documented that, in control samples, filamentous structures connecting two platelets occurred with comparable frequency to filamentous structures connecting platelets with the fibrin surface (data not shown). In contrast to control samples, such filamentous structures were completely absent when fibrin was perfused with blood of a patient with severe vWD (Fig 3B) . These samples also lacked immunogold staining for vWF.
When fibrin-coated formvar grids were perfused with whole blood from a patient with Bernard-Soulier syndrome, only small clusters of gold were found around the granulomere, but filamentous structures staining for vWF were not seen (Fig 3D) . Comparable results were obtained when an antibody against GPlb was included in normal donor blood perfusions (data not shown).
Binding of vWF tojbrin(ogen).
To investigate the binding of vWF to fibrin(ogen), microtiter plates were coated with fibrinogen and subsequently incubated with purified vWF or normal pool plasma. The amount of vWF bound was detected with a peroxidase-coupled antibody directed against vWF. Whereas purified vWF adhered well to fibrinogen, no binding of plasma vWF could be detected when fibrinogen-coated wells were incubated with plasma (Fig 4) .
To study the binding of plasma vWF to fibrin under flow conditions, fibrin-coated formvar grid coverslips were perfused with normal plasma containing red blood cells but not platelets. Immunogold staining for vWF could not be detected on the fibrin-coated surface (data not shown). This finding is directly in contrast to the finding of filamentous vWF strands (Fig 3A) interacting with the fibrin surface when platelets were present.
Participation of platelets in the interaction of vWF with jhrin. To determine if the presence of platelets was necessary for the interaction between vWF and fibrin, double perfusions were performed in which the fibrin surface was first perfused for 5 minutes with vWF-depleted plasma or normal plasma and red blood cells. Severe vWD blood or control blood was used in the second perfusion. A low platelet coverage with severe vWD blood was seen when vWF-depleted plasma or normal plasma was used in the first perfusion ( Table 2 ). The platelet coverage of severe vWD blood or respectively. Note the large filamentous structures stained for vWF connecting two platelets or a platelet and the fibrin surface in the control sample, the absence of vWF staining in the severe vWD sample, and gold clusters but no filaments on platelets of a GPlb-deficient patient.
control blood did not change with the preperfused fibrin surfaces. Platelet adhesion increased only when purified plasma vWF was added to severe vWD blood (Table I) . Irtternction of vWF with GPIIb:IIIn. GPI1b:IIIa is essential for the direct interaction of platelets with fibrin. A possible participation of the interaction of vWF with GPI1b:IIIa in platelet-fibrin interaction was studied with mutant vWF in which was replaced by a GIy"'" to obtain an RGGS sequence (D1746G-vWF). When D1746G-vWF was added to blood of a patient with severe vWD, platelet adhesion was higher than in the absence of D1746G-vWF and reached even higher levels when wild-type vWF was added (Fig S) . As a control, a mutant vWF missing the A1 domain was used (AAI-vWF).?" The AI domain contains the GPlb binding site of vWF. When AAI-vWF was added to severe vWD blood and subsequently perfused over fibrin, no restoration of platelet adhesion was found.
This finding strongly suggests that the interaction between GPllb:Illa and vWF is not important for the supporting role of vWF in platelet-fibrin interaction under flow conditions. To confirm this, perfusions were performed in which control blood was preincubated with an MoAb against vWF that selectively blocks the binding of vWF to GPIlb:llla (152B6)."' No inhibition of platelet adhesion was found (Fig  6) . Similar results were obtained with washed platelets and red blood cells reconstituted in HAS (Fig 7) . Control antibodies also did not inhibit platelet adhesion (Fig 6; RAgS0 and IgG2.2.9). In contrast, platelet-fibrin interactions were almost completely inhibited by an MoAb against vWF recognizing the GPIb binding site (Figs 6 and 7; RAg35) or by an MoAb against GPIb (Fig 6; AK2) . A combination of the antibodies against vWF did not cause any additional inhibition of platelet adhesion to fibrin (Fig'6 : Dbl).
DISCUSSION
We have studied here in detail the participation of vWF in platelet-fibrin interaction at high shear rate. For optimal adhesion it is apparently necessary that both vWF and platelets are present together to support the adhesion process. When surface-bound fibrinogen was incubated with plasma (Fig 4) or when fibrin was perfused with plasma and red blood cells, no detectable binding of vWF was found. This suggests that other plasma proteins able to bind to fibrin are present in higher concentrations andor have a higher affinity than vWF for fibrinogen." Moreover, when fibrin was first perfused with plasma and red blood cells and in a second perfusion exposed to whole blood from a patient with severe vWD, minimal platelet adhesion was found, as was seen for perfusion with severe vWD blood alone. Adhesion of severe vWD platelets was only restored when plasma vWF was present in the second perfusion (Tables 1 and 2 ).
These observations indicate that platelets participate directly in the association between vWF and fibrin. This hypothesis is supported by the observation that, when fibrin was perfused with platelets lacking GPIb, the major binding site for vWF on platelets, hardly any interaction between vWF and fibrin was observed (Fig 3C) . Thus, it seems that vWF must first bind to platelets before it can interact with fibrin. The underlying molecular mechanism is not clear but may be explained by two effects. First, the local concentration of vWF will be increased as more v W F filaments are held near the fibrin surface. This will enhance binding through a mass action effect. Second, there is an entropy term that must be considered in any binding vWF bound to immobilized fibrin has less mobility then vWF in solution. This loss of freedom is entropy-unfavorable vWF-depleted plasma or normal plasma containing red blood cells was used in the first perfusion (see Materials and Methods for details). In the second perfusion, whole blood from a patient with severe vWD was used. Results were obtained in 5-minute blood perfusion experiments at a wall shear rate of 1,600/s. The results are expressed as the mean f SD percentage of surface covered by adherent platelets.
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and must be overcome by a favorable energetic effect due to the interaction between vWF and fibrin. For a long flexible molecule such as vWF, this entropy term is large and is probably not overcome by the gain in energy. When vWF first binds to GPIb, the entropy of the system has decreased and the binding of vWF to fibrin become less thermodynamically unfavorable.
Morphologic observations showed that, at high shear rate, platelets often adhered in bands in the direction of flow (Fig  1) . The fibrin to which the platelets adhered was formed under static conditions, resulting in a nearly random distribution of fibrin strands. At low shear rate, the surface was covered with platelets without a specific band pattern. Thus, the band pattern observed at high shear rate was not due to adhesion of platelets along prealigned fibrin strands. This band pattern suggests that the first platelet bound to the fibrin layer enabled the next platelet to adhere. Similar morphologic observations have been reported for another vWF-free adhesive surface, the fibroblast extracelluar matrix, on which platelets were also deposited also in bands in the direction of Immunoelectron microscopy studies showed filamentous structures staining for vWF between adjacent platelets and also filamentous structures staining for vWF that extended from platelets to the fibrin surface. The band pattern of platelets adhering to fibrin was absent with blood of a patient with Bernard-Soulier syndrome or with severe vWD blood, but reappeared when exogenous vWF was present in the severe vWD blood. Thus, vWF interaction with GPIb on the platelet membrane seems to be responsible for the band formation and caused the mutual interaction between platelets in the direction of flow. At low shear rate, at which platelet adhesion is almost independent of vWF, the band pattern was absent.
The role of vWF-GPIhIIIa interactions in platelet adhesion to fibrin was also studied with vWF mutants. These genetically engineered variants were added to severe vWD blood. When D1746G-vWF or wild-type vWF was added to severe vWD blood, higher platelet adhesion was seen than in the absence of D1746G-vWF or wild-type vWF ( For personal use only. on August 30, 2017. by guest www.bloodjournal.org From and the platelets adhered in bands in the flow direction. Addition of vWF in which the GPIb-binding site had been deleted resulted in a low platelet adhesion to fibrin, indicating that only vWF-GPIb and not vWF-GPI1b:IIIa interaction is involved in the supportive effect of vWF. This was supported with results obtained with whole normal blood or reconstituted blood and an antibody that selectively inhibits the binding of v W F to GP1Ib:IIIa (Figs 6 and 7) . These results showed that inhibition of the RGD-site in v W F had no effect on platelet adhesion in whole normal blood. Thus, only vWF-GPIb and not vWF-GP1Ib:IIIa is involved in the adhesion of platelets to fibrin. This means that soluble vWF binds to GPIb on a spread platelet. This indicates that GPIb, just like GPIIb:IIIA, goes through a process of activation, making the receptor available for its soluble ligand. Although such an event has never been described for GPIb, all the experiments performed in the study support the existence of such an event.
In addition to plasma, vWF is also present in the a-granules of platelets, and platelet vWF can provide v W F necessary for the adhesion to fibrin (Fig 7) . We cannot exclude the possibility that, when platelet adhesion to fibrin studied in whole blood is supported by platelet-vWF, vWFGPI1b:IIIa does play a role. However, perfusion studies with washed platelets and red blood cells in a human albumin solution showed the vWF-GPIb dependency as tested by antibodies, whereas almost no inhibition of platelet adhesion was observed by the antibody that specifically blocks vWFGP1Ib:IIIa (Fig 7) . This strongly suggests that also plateletreleased vWF supports platelet-fibrin interactions via GPIb and not via GP1Ib:IIIa. Also, our studies have shown that Bernard-Soulier syndrome platelets, which contain v W F in their a-granula and express GPIIb:IIIa, did not exhibit v W Fdependent adhesion to fibrin ( Table 1 and Fig 3C) . No information could be gained with platelets of Glanzmann's thrombasthenic patients. Due to the lack of GPI1b:IIIa adhesion was too low to draw conclusions about possible interactions between v W F and GPI1b:IIIa.
It should be emphasized that all the studies described here are performed at high shear rate for 5 minutes. It is therefore difficult to compare these experiments with static experi- ments in which washed platelets were allowed to adhere to fibrinogen for 45 minutes.3 Under these latter conditions, platelets can become activated, which may strongly influence the results.
In summary, we have shown here with v W F mutants and specific antibodies that binding of exogenous v W F to GPI1b:IIIa is not necessary for platelet adhesion to fibrin at a wall shear rate of 1,6OO/s. We were unable to define a role of vWF-GP1Ib:IIIa in platelet aggregate formation, because, in our system, hardly any raised aggregates were formed.
Taking our data together, the following hypothesis can be proposed for platelet adhesion to fibrin at high shear rate. A nonstimulated platelet adheres to fibrin via GP1Ib:IIIa. At low shear rate, the affinity of GP1Ib:IIIa for fibrin is strong enough to support optimal adhesion. At high shear rate, vWF is necessary to increase the affinity of the platelets for fibrin. After adhesion of the first platelet, plasma or platelet-released v W F binds GPIb on the adherent platelets. The platelet definitely participates in binding of the vWF molecule to the fibrin, but the mechanism for this effect remains unclear. Platelet-bound vWF can serve as a new binding site for a next unactivated platelet from the circulation. After the next platelet has adhered to v W F , this platelet also interacts with the fibrin surface via GP1Ib:IIIa. Through this multivalent interaction, adherent platelets can withstand the shear forces of the blood. These tightly adherent platelets provide new starting points for adhesion of additional platelets from the circulation. The shear forces of the blood are then responsible for the alignment of platelets in the direction of flow.
